ABVC BioPharma, Inc. - Common Stock (ABVC)
Frequently Asked Questions About ABVC BioPharma, Inc. - Common Stock (ABVC)
Does ABVC have any partnerships or collaborations?
Yes, ABVC BioPharma actively seeks partnerships and collaborations with other biopharmaceutical companies, research institutions, and academic organizations. These collaborations are aimed at leveraging complementary expertise and resources to accelerate the development of its therapeutic programs.
How can investors follow ABVC's progress?
Investors can follow ABVC BioPharma's progress through various channels, including its official website, press releases, and SEC filings. The company also participates in investor conferences and provides updates on its clinical developments and strategic initiatives.
How does ABVC approach drug delivery?
ABVC BioPharma utilizes its proprietary drug delivery technologies to enhance the absorption and efficacy of its therapeutic candidates. The company focuses on novel formulations that aim to improve the pharmacokinetics of its drugs, ultimately enhancing treatment outcomes for patients.
How does ABVC fund its operations?
ABVC BioPharma funds its operations through a combination of public equity financing, strategic partnerships, and grant funding. These diverse sources of capital are essential for supporting the company’s research and development efforts and operational growth.
How does ABVC handle intellectual property?
ABVC BioPharma actively protects its intellectual property through patents and other legal means. By securing its innovations, the company aims to safeguard its competitive advantages and ensure its unique technologies and products are protected from infringement.
How does ABVC prioritize its drug candidates?
ABVC BioPharma prioritizes its drug candidates based on factors such as market potential, therapeutic need, and the likelihood of clinical success. The company employs a structured evaluation process to ensure the efficient allocation of resources to the most promising projects.
Is ABVC BioPharma publicly traded?
Yes, ABVC BioPharma, Inc. is a publicly traded company listed on the Nasdaq stock exchange under the symbol 'ABVC'. Being publicly traded allows the company to raise capital to fund its research and development initiatives.
What are ABVC's recent achievements?
Recent achievements of ABVC BioPharma include advancements in its clinical programs and successful completion of key milestones in drug development. The company continues to make progress in its trials, demonstrating its commitment to bringing innovative therapies to patients.
What does ABVC BioPharma, Inc. do?
ABVC BioPharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for various medical conditions. Its primary areas of interest include neurological disorders, oncology, and other diseases with significant unmet medical needs. The company aims to leverage its proprietary drug delivery technologies and unique therapeutic candidates to provide effective treatment options that could improve patients' quality of life.
What is ABVC's approach to corporate social responsibility?
ABVC BioPharma is committed to corporate social responsibility (CSR) by prioritizing ethical business practices, sustainability, and engagement with local communities. The company believes that its role extends beyond just developing innovative therapies to include positive contributions to society.
What is ABVC's stock symbol?
ABVC BioPharma, Inc. trades on the Nasdaq exchange under the stock symbol 'ABVC'. This designation helps investors and market participants easily identify the company's shares on the stock market.
What is ABVC's vision for the future?
ABVC BioPharma envisions becoming a leading biopharmaceutical company recognized for its innovative therapeutics that transform the treatment landscape for serious diseases. The company aims to continuously expand its pipeline and bring novel solutions to market that address critical medical needs.
What is the importance of its proprietary technologies?
ABVC BioPharma's proprietary drug delivery technologies play a crucial role in its therapeutic development. These technologies aim to improve the bioavailability and therapeutic efficacy of its products, providing a competitive edge in the biopharmaceutical market.
What is the primary focus of ABVC's research?
The primary focus of ABVC BioPharma's research lies in the development of drug candidates for neurological disorders and oncology. The company emphasizes a robust pipeline of therapeutics that utilize advanced formulations and drug delivery methods to enhance efficacy and minimize side effects.
What regulatory approvals does ABVC seek?
ABVC BioPharma seeks regulatory approvals from the U.S. Food and Drug Administration (FDA) and other relevant health authorities for its drug candidates. These approvals are critical for conducting clinical trials and ultimately bringing new therapies to market.
What stage are ABVC's drug candidates currently in?
ABVC BioPharma has several drug candidates in various stages of clinical development, ranging from preclinical studies to late-stage clinical trials. The company continuously evaluates its pipeline to prioritize candidates with the most potential for successful commercialization.
What therapeutic areas does ABVC target?
ABVC BioPharma targets several therapeutic areas, primarily focusing on neurological diseases, cancer, and other health conditions with significant unmet medical needs. By addressing these areas, ABVC seeks to develop therapies that can provide meaningful improvements in patient care.
When was ABVC BioPharma, Inc. founded?
ABVC BioPharma, Inc. was founded in 2012. Since its inception, the company has been dedicated to advancing innovative therapies for serious health conditions, utilizing cutting-edge research and technology to drive its development programs.
Where is ABVC BioPharma, Inc. headquartered?
ABVC BioPharma, Inc. is headquartered in Fremont, California. This strategic location allows the company to be in proximity to one of the most vibrant biotech and pharmaceutical hubs in the United States, fostering collaborations and access to talented professionals in the industry.
Who are the key executives at ABVC?
ABVC BioPharma's leadership team includes experienced professionals with extensive backgrounds in biopharmaceutical development, finance, and operational management. Their expertise helps to guide the company’s strategic direction and drive its research and development initiatives.
What is the current price of ABVC BioPharma, Inc. - Common Stock?
The current price of ABVC BioPharma, Inc. - Common Stock is 0.7420
When was ABVC BioPharma, Inc. - Common Stock last traded?
The last trade of ABVC BioPharma, Inc. - Common Stock was at 4:00 pm EDT on April 4th, 2025
What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?
The market capitalization of ABVC BioPharma, Inc. - Common Stock is 18.12M
How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?
ABVC BioPharma, Inc. - Common Stock has 24.42M shares outstanding.